Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker

Telomere length appears to correlate with survival in early non-small-cell lung cancer (NSCLC), but the prognostic impact of telomere status in advanced NSCLC remains undetermined. Our purpose was to evaluate telomere parameters as prognostic and predictive biomarkers in advanced NSCLC. In 79 biopsi...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-01, Vol.15 (1), p.290
Main Authors: Faugeras, Eve, Véronèse, Lauren, Jeannin, Gaëlle, Janicot, Henri, Bailly, Sébastien, Bay, Jacques-Olivier, Pereira, Bruno, Cayre, Anne, Penault-Llorca, Frédérique, Cachin, Florent, Merle, Patrick, Tchirkov, Andrei
Format: Article
Language:English
Subjects:
Biological markers
Biomarkers
Biopsy
Cancer
Cancer therapies
Cell division
Chemotherapy
Gene expression
Genetic aspects
Health aspects
Immunotherapy
Kinases
Life Sciences
Lung cancer
Lung cancer, Non-small cell
Medical prognosis
Multivariate analysis
Mutation
Non-small cell lung carcinoma
Patients
Prognosis
Proteins
Rap1 protein
Sensitivity analysis
Small cell lung carcinoma
Software
Statistical analysis
Survival analysis
Telomerase
Telomere-binding protein
Telomeres
TRF2 protein
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Telomere length appears to correlate with survival in early non-small-cell lung cancer (NSCLC), but the prognostic impact of telomere status in advanced NSCLC remains undetermined. Our purpose was to evaluate telomere parameters as prognostic and predictive biomarkers in advanced NSCLC. In 79 biopsies obtained before treatment, we analyzed the telomere length and expression of and shelterin complex genes ( , , , , , and ), using quantitative PCR. Non-responders to first-line chemotherapy were characterized by shorter telomeres and low expression ( = 0.0035 and = 0.0069), and tended to show higher levels ( = 0.058). In multivariate analysis, short telomeres were associated with reduced event-free (EFS, = 0.0023) and overall survival (OS, = 0.00041). and overexpression correlated with poor EFS ( = 0.0069 and = 0.00041) and OS ( = 0.0051 and = 0.007). Low and expression-levels were linked to reduced EFS ( = 0.00032 and = 0.0069) and OS ( = 0.000051 and = 0.02). Short telomeres were also associated with decreased survival after nivolumab therapy ( = 0.097). Evaluation of telomere status in advanced NSCLC emerges as a useful biomarker that allows for the selection of patient groups with different clinical evolutions, to establish personalized treatment.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15010290